These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
629 related articles for article (PubMed ID: 26378644)
1. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Anstee QM; Day CP Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644 [TBL] [Abstract][Full Text] [Related]
2. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712 [TBL] [Abstract][Full Text] [Related]
3. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529 [TBL] [Abstract][Full Text] [Related]
5. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348 [TBL] [Abstract][Full Text] [Related]
6. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
7. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP). Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356 [TBL] [Abstract][Full Text] [Related]
8. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781 [TBL] [Abstract][Full Text] [Related]
9. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269 [TBL] [Abstract][Full Text] [Related]
10. Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. Valenti LVC; Baselli GA Curr Pharm Des; 2018; 24(38):4566-4573. PubMed ID: 30659533 [TBL] [Abstract][Full Text] [Related]
11. Genetics and epigenetics of NAFLD and NASH: Clinical impact. Eslam M; Valenti L; Romeo S J Hepatol; 2018 Feb; 68(2):268-279. PubMed ID: 29122391 [TBL] [Abstract][Full Text] [Related]
12. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK; J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765 [TBL] [Abstract][Full Text] [Related]
13. A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Targher G; Byrne CD Metab Syndr Relat Disord; 2015 Aug; 13(6):235-8. PubMed ID: 25714786 [TBL] [Abstract][Full Text] [Related]
14. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682 [TBL] [Abstract][Full Text] [Related]
15. Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond. Krawczyk M; Liebe R; Lammert F Gastroenterology; 2020 May; 158(7):1865-1880.e1. PubMed ID: 32068025 [TBL] [Abstract][Full Text] [Related]
16. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Krawczyk M; Portincasa P; Lammert F Semin Liver Dis; 2013 Nov; 33(4):369-79. PubMed ID: 24222094 [TBL] [Abstract][Full Text] [Related]
17. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Wainwright P; Byrne CD Int J Mol Sci; 2016 Mar; 17(3):367. PubMed ID: 26978356 [TBL] [Abstract][Full Text] [Related]
18. The genetics of NAFLD. Anstee QM; Day CP Nat Rev Gastroenterol Hepatol; 2013 Nov; 10(11):645-55. PubMed ID: 24061205 [TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237 [TBL] [Abstract][Full Text] [Related]
20. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]